文献速递免疫规划传染病防控与疫情报告

BNT162b2(辉瑞-BioNTech)疫苗在12-17岁青少年中预防SARS-CoV-2感染的疫苗效果 interim 估计——亚利桑那州,2021年7月至12月

Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-12-31

在亚利桑那州243名12-17岁青少年的前瞻性队列中,每周无论症状进行RT-PCR检测,2021年7月25日至12月4日期间Delta变异株为主要流行株。完全接种BNT162b2疫苗预防SARS-CoV-2感染的疫苗效果估计为92%(95%CI=79%-97%),调整了社会人口学特征、健康信息、社交接触频率、口罩使用、地点和本地病毒流行。CDC建议所有符合条件者包括12-17岁人群接种COVID-19疫苗。

要点

  • 完全接种BNT162b2疫苗预防SARS-CoV-2感染的疫苗效果为92%(95%CI=79%-97%)。
  • 研究期间Delta变异株为主要流行株,采用每周RT-PCR检测无论症状。
  • CDC建议所有符合条件者包括12-17岁人群接种COVID-19疫苗。

核心结论

  • 真实世界数据表明,2剂BNT162b2疫苗在亚利桑那州青少年中预防SARS-CoV-2感染高度有效。
  • CDC建议所有符合条件者包括12-17岁人群接种COVID-19疫苗。

研究设计与样本

  • 前瞻性队列研究,纳入亚利桑那州243名12-17岁青少年,2021年7月25日至12月4日期间每周无论症状及出现COVID-19样疾病时进行RT-PCR检测。
  • 190名青少年贡献完全接种人时(接种2剂BNT162b2疫苗后≥14天),30名贡献部分接种人时(接种1剂或接种2剂但第二剂完成<14天),66名贡献未接种人时。

主要发现

  • 完全接种BNT162b2疫苗预防SARS-CoV-2感染的疫苗效果估计为92%(95%CI=79%-97%),调整社会人口学特征、健康信息、社交接触频率、口罩使用、地点和本地病毒流行。
  • 研究期间SARS-CoV-2 B.1.617.2(Delta)变异株为主要流行株。

关键数值与推荐

  • 完全接种BNT162b2疫苗预防SARS-CoV-2感染的疫苗效果为92%(95%CI=79%-97%)。

临床怎么用

  • CDC建议所有符合条件者包括12-17岁人群接种COVID-19疫苗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine has demonstrated high efficacy in preventing infection with SARS-CoV-2 (the virus that causes COVID-19) in randomized placebo-controlled Phase III trials in persons aged 12-17 years (referred to as adolescents in this report) (1); however, data on real-word vaccine effectiveness (VE) among adolescents are limited (1-3). As of December 2021, the Pfizer-BioNTech vaccine is approved by the Food and Drug Administration (FDA) for adolescents aged 16-17 years and under FDA emergency use authorization for those aged 12-15 years. In a prospective cohort in Arizona, 243 adolescents aged 12-17 years were tested for SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) each week, irrespective of symptoms, and upon onset of COVID-19-like illness during July 25-December 4, 2021; the SARS-CoV-2 B.1.617.2 (Delta) variant was the predominant strain during this study period. During the study, 190 adolescents contributed fully vaccinated person-time (≥14 days after receiving 2 doses of Pfizer-BioNTech vaccine), 30 contributed partially vaccinated person-time (receipt of 1 dose or receipt of 2 doses but with the second dose completed <14 days earlier), and 66 contributed unvaccinated person-time. Using the Cox proportional-hazards model, the estimated VE of full Pfizer-BioNTech vaccination for preventing SARS-CoV-2 infection was 92% (95% CI = 79%-97%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local virus circulation. These findings from a real-world setting indicate that 2 doses of Pfizer-BioNTech vaccine are highly effective in preventing SARS-CoV-2 infection among Arizona adolescents. CDC recommends COVID-19 vaccination for all eligible persons in the United States, including persons aged 12-17 years.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Lutrick K, Rivers P, Yoo YM, et al. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34968373. doi:10.15585/mmwr.mm705152a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。